Incidence of cytogenetic abnormalities recorded serially after initiation of treatment.

(A) Incidence of select cytogenetic abnormalities (no cytogenetic abnormalities, no CA; hypodiploid or CA 13; other CAs) before the study and on serial follow-up. Note that, at diagnosis, 33% of patients had CAs, approximately evenly divided between hypodiploid/CA 13 and other CAs. Over time, presumably as a result of effective therapy, the proportion of patients with CAs decreased to a low 15%. Eventually, the incidence of hypodiploid CAs/CA 13 among those with CAs increased. (B) Increase in the cumulative incidence of CAs during the disease course. Cumulative incidence, from start of Total Therapy I, of CAs and adverse prognostic subgroups (CA 13, hypodiploidy).